Inclusion Criteria:

• Parents or legal guardian signed-written informed consent
• 1 to < 18 years of age
• Histologically or cytologically confirmed solid tumor that has recurred after standard therapy, or for which there is no standard therapy.
• Paraffin-embedded tumor tissue from primary tumor or metastasis for determination of epidermal growth factor receptor expression and biomarker testing
• Tumor expressing EGFr by immunohistochemistry.
• Presence of measurable or non-measurable disease.
• Life expectancy of >/= 12 weeks.
• Performance status: Karnofsky >/= 60% for 12 to <18 years of age; Lansky play scale >/= 60% for 1 to < 12 years of age.
• Adequate hematologic function.
• Adequate renal function.
• Adequate hepatic function.
• Magnesium >/= LLN
• Adequate pulmonary function
• All previous therapy-related toxicities must have resolved or return to baseline.

Exclusion Criteria:

• Diagnosis of leukemia, non-Hodgkin's lymphoma, Hodgkin's disease or other hematologic malignancy.
• Any prior allogeneic transplant.
• Prior autologous bone marrow or peripheral stem cell transplant less than 3 months prior to enrollment.
• Substantial radiotherapy to the bone marrow within 6 weeks prior to enrollment.
• Prior use of any monoclonal antibodies directly targeting the EGFr. Subjects who have received prior tyrosine kinase inhibitors such as gefitinib or erlotinib are eligible.
• Immunotherapy, radiotherapy, or chemotherapy </= 2 weeks prior to enrollment. (</= 6 weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin, and </= 6 weeks from prior antibody therapy).
• Requirement to receive concurrent chemotherapy, immunotherapy, radiotherapy (except for pain control) or any other investigational drug while on this study.
• Prior seizures < 3 months prior to enrollment. Subjects with a history of seizure disorders >/= 3 months prior to enrollment must be seizure free and on stable anticonvulsant medication(s) for >/= 3 months prior to enrollment).
• Presence of a serious uncontrolled medical disorder.
• Dementia, altered mental status, or any other medical condition or disorder that would prohibit the understanding or rendering of assent (if applicable), or ability to comply with study procedures.
• Major surgery </= 28 days prior to enrollment.
• Known or suspected history of interstitial lung disease.
• Active inflammatory bowel disease or other bowel disease causing chronic diarrhea.
• Known positive test for human immunodeficiency virus infection, hepatitis C virus, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity.
• Males of reproductive potential unwilling to use adequate contraception for the duration of the study and for 1 month after the last administration of investigational product.
• Females of childbearing potential not using adequate contraception for the duration of the study and for 6 months after the last administration of investigational product.
• Pregnant or breast-feeding.
• Received investigational therapy or procedure </= 30 days prior to enrollment.